Kornimate/medical-research-clean huggingface dataset:
qbsafe: a novel approach to diabetes management focused on quality of life, burden of treatment, social integration and avoidance of future events

Conditions: Diabetes; Diabetes Mellitus

Summary: the purpose of this study is to co-develop a toolkit (known as the qbsafe toolkit) with patients, family caregivers, and clinicians that focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety for patients with diabetes mellitus.


Eligibility criteria:
inclusion criteria: -existing diagnosis of diabetes mellitus; have an existing appointment with a participating clinician exclusion criteria: * do not speak english * severe vision/hearing impairment * unable to give informed consent for any reason
the influence of an acute exacerbation during pulmonary rehabilitation in copd patients awaiting lung transplantation

Conditions: Chronic Obstructive Pulmonary Disease

Summary: data from chronic obstructive pulmonary disease patients awaiting lung transplantation which performed a pulmonary rehabilitation program will be analyzed retrospectively. acute exacerbations occur frequently in these patients and have a major impact on the course of the disease. this study investigates the prevalence and the impact of acute exacerbations during pulmonary rehabilitation in patients with severe chronic obstructive pulmonary disease patients awaiting lung transplantation that continued the rehabilitation program despite an acute exacerbation. data will be taken from the internal database of the reference center (schoen klinik berchtesgadener land, schoenau, germany) where these data were collected during clinical routine.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of chronic obstructive pulmonary disease including patients with alpha-1 antitrypsin deficiency * listed for lung transplantation or in the evaluation process for lung transplantation * performed a pulmonary rehabilitation program at the reference center exclusion criteria: * patients that discontinued the pulmonary rehabilitation program due to any reason and could therefore not perform assessement tests at the end of regular rehabilitation program

Keywords: copd exacerbation copd pulmonary rehabilitation lung transplantation acute exacerbation waiting list end-stage lung disease
healing touch and relaxation therapies in cervical cancer patients

Conditions: Cervix Neoplasms

Summary: the purpose of this study is to evaluate the effects of healing touch and relaxation therapy on cervical cancer patients undergoing chemotherapy and radiation treatment.

the side effects of chemotherapy and radiation treatment are often severe and can have devastating effects on the mental and physical well-being of cancer patients. this study will determine whether healing touch and relaxation therapy are effective in minimizing the side effects of chemotherapy and radiation treatment in cervical cancer patients. participants in this study will receive weekly chemotherapy and daily radiation treatments for 6 weeks. participants will be randomly assigned to receive either standard care (sc), sc plus relaxation therapy, or sc plus healing touch therapy. the relaxation therapy consists of progressive muscle relaxation and guided imagery. the healing touch therapy involves an energy-based modality in which health care practitioners stimulate the energy fields surrounding the patient. a physician-completed assessment and measures of immune function will be used to assess the well-being and overall quality of life of participants.

Eligibility criteria:
inclusion criteria: * stage ib1-iva cervical cancer * treatment with concurrent chemotherapy and radiation at the university of iowa hospitals and clinics exclusion criteria: * immunosuppressive disorders * use of immunosuppressive medications * transplant recipient * metastatic or recurrent cervical cancer * history of any other type of cancer

Keywords: relaxation techniques radiation drug therapy healing touch
efficacies of different managements in patients with trigger finger

Conditions: Trigger Finger

Summary: the aim of the study is to compare the effectiveness of peritendinous steroid injection under ultrasound guidance and percutaneous a1 pulley release procedures in terms of disease stage, pain, and severity of locking in patients with trigger finger.

this study was designed as a randomized, controlled, prospective study. patients who had been experiencing trigger finger symptoms for at least one month and who presented to the gaziler physical medicine and rehabilitation training and research hospital, affiliated with the health sciences university faculty of medicine patients were randomly divided into two groups: the peritendinous steroid group (n=15) and the percutaneous pulley release group (n=15). in the first group, under ultrasound guidance, a mixture of 1 ml corticosteroid (2 mg+5 mg/ml betamethasone) and 1 ml local anesthetic (20 ml 2% prilocaine) was injected peritendinously between the a1 pulley and the flexor tendon sheath. in the second group, a percutaneous a1 pulley release procedure was performed under ultrasound guidance using a 20 g needle, followed by peritendinous injection of the same mixture of corticosteroid and local anesthetic. patients were evaluated four times: before treatment, at 1 week, 1 month, and 3 months after treatment. modified quinnel classification, vas (visual analog scale), and severity of locking scales were used as outcome measures in the study.

Eligibility criteria:
inclusion criteria: * being over 18 years of age * having had trigger finger complaints for more than 1 month * not having received any injections for trigger finger diagnosis within the last 1 month * signing the informed consent form indicating willingness to participate in the study exclusion criteria: * refusing to participate in the study * presence of partial or complete tendon rupture in the relevant tendon of the finger to be treated * presence of wounds and infection in the area where the procedure will be performed * pregnancy status * history of allergy to the injected medications (local anesthetic, steroid)
an intervention to decrease infant crying

Conditions: Colic

Summary: this is a study looking at the happiest baby on the block technique. the investigators hypothesized that infants of mothers given a 30 minute videotape demonstrating the happiest baby on the block technique would fuss/cry less and sleep longer than infants of mothers given a 30 minute videotape on general newborn care. the investigators also hypothesized that mothers given the happiest baby on the block videotape would have lower levels of stress.

mothers recorded their babies fussing, crying and sleeping on paper diaries when their infants were 1, 4, 6, 8 and 12 weeks old.

Eligibility criteria:
inclusion criteria: mothers of singleton newborns * 37 to 41 week gestation * healthy (no icu admission) exclusion criteria: * not able to view videotape at home * not able to speak english

Keywords: colic crying clinical trial
ridge preservation comparing a flap versus flapless technique

Conditions: Jaw, Edentulous, Partially

Summary: to compare a flapless technique of alveolar ridge preservation to a flap technique to determine if preserving the periosteal blood supply would prevent loss of crestal ridge width and height.

twenty-four patients will randomly be assigned to receive ridge preservation using either flapless or flap technique. twelve test patients will receive ridge preservation using a flapless approach and twelve control patients will receive ridge preservation using a flap technique. all sockets will be grafted with demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier. re-entry surgery will be performed at 4 months when a trephine core will be taken from the grafted site immediately prior to implant placement and submitted for histologic processing.

Eligibility criteria:
inclusion criteria: 1. have one non-molar tooth requiring extraction that will be replaced with a dental implant where at least one adjacent tooth is present 2. study subjects at least 18 years old 3. patients must sign an informed consent approved by the university of louisville human studies committee of institutional review board. exclusion criteria: 1. patients with debilitating systemic disease, or a disease affects the periodontium 2. have an allergy to any material or medication used in the study 3. require prophylactic antibiotics 4. previous head and neck radiation therapy 5. chemotherapy in the previous 12 months 6. patients taking long term non-steroidal anti-inflammatory drugs or steroid therapy 7. smoked more than one pack of cigarettes per day
paclitaxel and capecitabine in patients with metastatic/recurrence esophageal cancer

Conditions: Esophageal Cancer

Summary: capecitabine is an orally administered fluoropyrimidine that is converted by 5-fu by thymidine phosphorylase (tp), preferentially in tumor tissues and has demonstrated activity as single agent in patients with gastrointestinal cancer. up-regulation of tp after taxane treatment in vitro suggested that there may be synergistic effects in combined treatment with taxane and capecitabine. the combination of taxane and capecitabine was reported to be highly active against non-small cell lung cancer, breast cancer, and stomach cancer.

paclitaxel-80 mg/m2/iv d1 \& d8 q 3 weeks capecitabine-900 mg/m2/po twice daily days 1-14 q 3 weeks patients receive treatment every 3 weeks till disease progression.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed esophageal cancer with histology of squamous carcinoma or adenocarcinoma 2. clinically diagnosed metastatic or recurrent esophageal cancer according to sixth edition of the ajcc cancer staging manual (appendix v) 3. at least 18 years old 4. disease status must be that of measurable disease defined as recist:lesions that can be accurately measured in at least one dimension \> 10 mm with chest x-ray, spiral ct scan or physical examination 5. ecog performance status 0-2 6. no prior radiotherapy to measurable lesion(s) but previous surgery and/or chest radiotherapy for the primary lesion is allowed 7. adequate major organ function including the following:hematologic function: wbc ≥ 3,500/mm3 or absolute neutrophil count (anc) ≥ 1,500/mm3, platelet count ≥ 100,000/mm3hepatic function: bilirubin ≤ 1.5 x unl , ast/alt levels ≤ 2.5 x unlrenal function: serum creatinine ≤ 1.5mg/dl 8. patients should sign an informed consent 9. if female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device \[iud\], birth control pills, or barrier device) during and for 3 months after trial. if male, use of an approved contraceptive method during the study and 3 months afterwards. females with childbearing potential must have a urine negative hcg test within 7 days prior to the study enrollment. exclusion criteria: 1. mi within preceding 6 months or symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmia 2. serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complication of study therapy 3. pregnant or nursing women 4. other malignancy with the past 5 years except adequately treated cutaneous basal cell carcinoma or uterine cervix in situ cancer 5. psychiatric disorder that would preclude compliance. 6. major surgery other than biopsy within the past two weeks

Keywords: esophageal cancer phase ii metastatic esophageal cancer recurrent esophageal cancer
safety and efficacy of latisse® in the augmentation of eyelashes of korean subjects

Conditions: Eyelash Hypotrichosis

Summary: this study will evaluate the safety and efficacy of latisse® (bimatoprost 0.03%) in the augmentation of eyelashes in korean women.


Eligibility criteria:
inclusion criteria: * eyelash prominence assessment of minimal or moderate * of korean ethnicity exclusion criteria: * any eye disease or abnormality * any ocular surgery or use of any eyelash extension or eyelash growth products within 3 months * any permanent eyeliner within 5 years * eyelash implants of any kind * eyelash tint or dye application within 2 months * use of any treatment that may affect hair growth within 6 months
integrated care and treatment for severe infectious diseases and substance use disorders among hospitalized patients

Conditions: Injection Site Infection; Substance Use Disorders

Summary: the goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (sud) clinical team intervention approach in patients hospitalized with severe injection-related infections (siri) who use drugs. the main question this study aims to answer is whether this intervention approach will be associated with lower mortality and fewer hospital readmissions. participants will participate in the integrated sud/id care team intervention (siri team). researchers will compare this intervention to treatment as usual (tua) to see if there are any differences in health outcomes.

the study intervention ("siri team") consists of a hospital-based multidisciplinary (id/sud consult) team that will provide intensive, integrated care for participants' id and sud both during the hospital stay and post-discharge for up to four months post-randomization. the siri team will provide low barrier access to medications and harm reduction services for sud; streamline id/sud treatment; provide longitudinal care with familiar providers; leverage different areas of expertise between physicians, advance practice providers, and patient navigators; and create patient-centered treatment plans, tailored to the individual, and informed by each patient's social circumstances, substance use, and personal goals/desires. the siri team intervention will be grounded in a harm reduction approach. the intervention duration is approximately 4 months. participants will complete follow-up visits at 4-, 8-, and 12-months post-randomization.

Eligibility criteria:
inclusion criteria: * be admitted to a participating hospital at the time of randomization * be 18 years of age or older * currently be experiencing a severe injection-related infection/siri or suspected siri * have an indication of injecting drugs in the prior year * provide informed consent * ability to communicate in english * provide sufficient locator information * sign a hipaa form and/or ehr release to facilitate record abstraction * report being willing to return for follow-up visits exclusion criteria: all individuals meeting any of the exclusion criteria will be excluded from study participation. specifically, individuals will be excluded from participation if they: * have significant cognitive or developmental impairment to the extent that they are unable to provide informed consent * (or their legal guardian/representative) are unable or unwilling to give written informed consent * are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities * are terminated via site principal investigator decision with agreement from one of the study lead investigators.

Keywords: substance use disorders severe injection-related infections randomized controlled trial hospital-based care harm reduction
knowledge and awareness of pelvic floor health

Conditions: Pelvic Floor Awareness

Summary: the aim of this study is to investigate the relationship between knowledge and awareness of pelvic floor health and dyspareunia, pelvic floor dysfunctions, and quality of life in postpartum women.


Eligibility criteria:
inclusion criteria: * being a native speaker of turkish * being in the first year of postpartum * women who had a vaginal delivery * primiparous women * women aged 18 and over exclusion criteria: * women who have not given birth * multiparous women * women who had a cesarean delivery * having difficulty to understanding evaluations
anti-pd-1 and chemotherapy for r/r hodgkin lymphoma

Conditions: Hodgkin Lymphoma

Summary: anti-pd-1 therapy provides high response rates in hodgkin lymphoma (hl) patients who have relapsed or are refractory (r/r) to autologous stem cell transplantation (asct) and brentuximab vedotin (bv), but median progression free survival (pfs) is only one year. the efficacy of treatment following anti-pd-1 is not well known. in this context, the optimal treatment for patients who failed after anti-pd-1 therapy is an issue. to better assess their outcome, the investigators retrospectively analyzed the characteristics and outcome of patients from 14 lysa (the lymphoma study association) centers who lost response to anti-pd-1 therapy and received additional ct.


Eligibility criteria:
inclusion criteria: * initial diagnosis of classical hl * optional histopathology confirmation of relapse/refractory hl, (2) age ≥ 18 years * eastern cooperative oncology group (ecog) performance status from 0 to 2 * patients must be have received: at least 2 prior regimens and have received or be ineligible for autologous stem cell transplant and must have received prior bv, and at least 2 cycles of single agent anti-pd-1 as last treatment before entering the study, * patients must have inadequate response to anti-pd-1 monotherapy (progressive disease or partial response according to lugano criteria) with at least one hypermetabolic lesion over the liver and mediastinum background at time of inclusion in the study * previous allogeneic stem cell transplant was allowed. patients treated with radiotherapy alone after anti-pd1 or combined with anti-pd1 treatment were not included in the study. exclusion criteria: - radiotherapy in the treatment after anti-pd1

Keywords: immunotherapy chemotherapy anti-pd1 re-sensibilization
prevalence of chronic inebriates to the emergency department and suitability for sobering house services

Conditions: Alcohol Intoxication

Summary: this study is intended to evaluate the prevalence of chronically inebriated patients in the emergeny department (ed). patients will be identified prospectively by screening all patients (24/7) presenting to the ed for one month. a running tally of all patients in the ed will be kept. of these patients, any patient that is noted to have alcohol intoxication will be identified. the chart of that patient will be reviewed for details about the patient's alcohol use and for the patient's suitability for a sobering house, which is a place where intoxicated patients can go to await sobriety. the chart will also be reviewed for the number of previous visits for alcohol use to our hospital ever and in the last year.

for this cross-sectional study, all patients presenting to the ed of an urban, level 1 trauma center for one month were prospectively screened by trained research associates. when an intoxicated patient was identified, study information including patient demographics, diagnoses, vital signs, blood alcohol concentration (bac), gcs on arrival, ability to ambulate independently on arrival, use of physical or chemical restraint, previous ed visits, length of stay, and health insurance was collected. data was analyzed using descriptive statistics.

Eligibility criteria:
inclusion criteria: * patients in the emergency department for alcohol intoxication exclusion criteria: * under 18 * prisoners * pregnancy
the added value of three-dimensional electroanatomic mapping for accurate delivery of pulsed field ablation in the pulmonary veins compared to pulsed field ablation with fluoroscopy and/or intracardiac echocardiography alone in the treatment of atrial fibrillation: map-pfa study

Conditions: Atrial Fibrillation (AF)

Summary: this is a randomized control trial that aims to evaluate the added value of electro-anatomical mapping to improve the quality of pulse field ablation lesions during atrial fibrillation ablation.

this is a multi-center randomized control trial, aims to compare the symmetry and centricity of pulmonary veins antral ablation lesions during positioning the ablation catheter with versus without the use of the faraview mapping system. the trial will enroll patients with atrial fibrillation, who are planned to undergo atrial fibrillation pulsed field ablation ablation using farawave catheter (the standard ablation catheter without faraview mapping software utilization) and faraview catheter (the upgraded catheter with features to utilize the farview mapping software) during the period of 2025. a total of 32 patients will be randomized in 1:1 ratio to either group of the trial. the aim is to enroll 16 patients from each participating institution (i.e. umcg and erasmus umc). all study candidates will be either assigned to faraview (group 1) or farawave (group 2). both groups will undergo post ablation high density intracardiac mapping (e.g. voltage mapping) with the orion mapping catheter, to assess the symmetry and centrality of the antral pulmonary veins' ablation lesions in relation to the pulmonary vein ostia. we propose an eccentricity index to compare and reflect the central location of the pulmonary veins' antral ablation lesions' margins relative to the pulmonary veins' ostia between the two groups.

Eligibility criteria:
inclusion criteria: * diagnosed with atrial fibrillation. * planned for ablation with pulsed field ablation technology. * able to consent for participation. exclusion criteria: -history of prior atrial fibrillation ablation.

Keywords: electroanatomical mapping pulsed field ablation atrial fibrillation the farapulse system farawave catheter faraview mapping software pulmonary vein isolation fluoroscopy intracardiac echocardiography high density mapping eccentricity index